Literature DB >> 31724099

Early Predictors of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease: Non-obese Versus Obese Patients.

Congxiang Shao1, Junzhao Ye1, Fuxi Li1, Yansong Lin1, Tingfeng Wu1, Wei Wang2, Shiting Feng3, Bihui Zhong4.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is regarded as a risk factor of cardiovascular disease (CVD). However, the association between non-obese NAFLD and CVD has not been well established. AIM: We aimed to compare the CVD risk between non-obese and obese NAFLD patients, and explored the factors associated with subclinical atherosclerosis.
METHOD: Consecutive NAFLD patients estimated by magnetic resonance imaging-based proton density fat fraction (MRI-PDFF) were recruited. Liver fat content (LFC) and liver stiffness were measured with MRI-PDFF and shear wave elastography, respectively. CVD risk was estimated by atherosclerosis index (AI), carotid intima-media thickness, carotid plaque, and Framingham risk score (FRS).
RESULTS: This study included 543 NAFLD patients. The presence of carotid intima-media thickening and carotid plaque, FRS, and AI were comparable between non-obese and obese patients. Age increased per 10 years (OR 9.68; P < 0.001) and liver fibrosis (liver stiffness > 6.1 kPa, OR 4.42; P = 0.004) were significant factors associated with carotid intima-media thickening in non-obese patients, while age increased per 10 years (OR 2.02; P < 0.001), liver fibrosis (OR 2.18; P = 0.039), and LFC > 10% (OR 2.29; P = 0.021) were independent predictors in obese patients. Only elevated triglyceride was significantly associated with carotid plaque in non-obese patients (OR 2.42; P = 0.033), while age increased per 10 years (OR 1.77; P = 0.002) and LFC > 10% (OR 2.83; P = 0.019) were significant predictors in obese patients.
CONCLUSIONS: Liver stiffness and age were strongly predictive of subclinical atherosclerosis in all NAFLD, while LFC was an additional predictor in obese NAFLD patients. Our findings highlight that early CVD screening strategy should be established for NAFLD patients according to different BMIs.

Entities:  

Keywords:  Cardiovascular diseases; Liver fat content; Liver fibrosis; Non-obese nonalcoholic fatty liver disease

Year:  2019        PMID: 31724099     DOI: 10.1007/s10620-019-05926-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  6 in total

1.  [Congxin Lunzhi Fang improves aortic atherosclerosis and regulates ACE2 expression in ApoE-/- mice].

Authors:  Y Gu; J Jiang; Y Zhang; Y Chen; Y Chen; W Jiang; Z Huang; F Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-11-20

2.  Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection.

Authors:  Ling Luo; Junzhao Ye; Congxiang Shao; Yansong Lin; Yanhong Sun; Shiting Feng; Wei Wang; Bihui Zhong
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

3.  Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.

Authors:  Lampros Chrysavgis; Eleftheria Ztriva; Adonis Protopapas; Konstantinos Tziomalos; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

4.  Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.

Authors:  Ashwini Arvind; Jacqueline B Henson; Stephanie A Osganian; Cheryl Nath; Lara M Steinhagen; Zoe N Memel; Arley Donovan; Oluwafemi Balogun; Raymond T Chung; Tracey G Simon; Kathleen E Corey
Journal:  Hepatol Commun       Date:  2021-09-02

Review 5.  Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.

Authors:  Karolina Drożdż; Katarzyna Nabrdalik; Weronika Hajzler; Hanna Kwiendacz; Janusz Gumprecht; Gregory Y H Lip
Journal:  Nutrients       Date:  2021-12-27       Impact factor: 5.717

6.  Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants.

Authors:  Kemin Li; Ji Li; Xiaoyun Cheng; Jing Wang; Jingnan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.